Business
MapLight Therapeutics Updates Expected Timing of Topline Results for Ongoing Phase 2 Studies to Q3 2026
SAN FRANCISCO and BOSTON, Jan. 09, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (MapLight) (Nasdaq: MPLT) today announced an update to the expected timing of topline results for its ongoing Phase 2 ZEPHYR and IRIS clinical studies, which are progressing ahead of schedule. The company’s Phase 2 ZEPHYR trial evaluating ML-007C-MA for the treatment of schizophrenia continues to enroll robustly, and topline results are now expected in the third quarter of 2026. The ZEPHYR study is a randomiz
About this update from Maplight Therapeutics, Inc.
[{"type":"image","alt":"MapLight Therapeutics, Inc.","displaySize":"","headline":null,"caption":"MapLight Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":54,"url":"https://media.zenfs.com/en/globenewswire.com/941d8d85f6b637b4194ef76437eebab4"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/4H.ijOyaLLSu8RB2vL9Vrw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTc2O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/941d8d85f6b637b4194ef76437eebab4","width":300,"height":54}},"lazy":false},{"type":"text","content":"SAN FRANCISCO and BOSTON, Jan. 09, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (MapLight) (Nasdaq: MPLT) today announced an update to the expected timing of topline results for its ongoing Phase 2 ZEPHYR and IRIS clinical studies, which are progressing ahead of schedule.","length":280,"tagName":"p"},{"type":"text","content":"The company’s Phase 2 ZEPHYR trial evaluating ML-007C-MA for the treatment of schizophrenia continues to enroll robustly, and topline results are now expected in the third quarter of 2026. The ZEPHYR study is a randomized, double-blind, placebo-controlled trial that is expected to enroll 300 hospitalized adult participants with schizophrenia experiencing acute exacerbation of psychosis.","length":389,"tagName":"p"},{"type":"text","content":"“The accelerated enrollment pace in the ZEPHYR trial allows us to narrow our timing guidance to the third quarter of 2026,” said Chris Kroeger, co-Founder and Chief Executive Officer of MapLight. “This momentum is testimony to our disciplined execution and commitment to advancing our programs efficiently while maintaining the highest quality standards.”","length":355,"tagName":"p"},{"type":"text","content":"In addition, following completion of enrollment in the Phase 2 IRIS trial for ML-004 in autism spectrum disorder, topline results for that study are now expected in the third quarter of 2026. The IRIS study is a double-blind, placebo-controlled trial that randomized approximately 160 adult and adolescent participants.","length":319,"tagName":"p"},{"type":"text","content":"About MapLight Therapeutics","length":27,"tagName":"p"},{"type":"text","content":"MapLight Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system disorders. The ...